Marvel has released a new Hellfire Gala that serves as an eulogy to one of the X-Men's greatest eras in comics.

Hellfire Vigil #1, on sale now from Marvel Comics. As I've discussed in the past, after John Byrne left Uncanny X-Men, writer ...

In previous years, the Hellfire Gala comics typically kicked off a big X-Men event. The X-Men: Hellfire Vigil #1 special is ...

Major future Storm revelations in this week's X-Men: Hellfire Vigil #1 (XSpoilers... no seriously, Big spoilers) ...

Hellfire Vigil #1 on Wednesday, and you can get yourself a sneak peek with the official preview of the issue below… One year ...

One year after the Hellfire Gala disaster, X-Men: Hellfire Vigil #1 brings mutants together for solidarity and celebration ...

A phase 2 study of Vigil Neuroscience’s iluzanebart has missed its biomarker and efficacy endpoints, prompting the Sanofi-bound biotech to stop a long-term extension trial of the TREM2 agonist.

The Hellfire missile is touted as being able to destroy any known tank in the world. It's a powerful missile that can be fired from the ground, sea, and air.

Finally, we end with an uncolored page by Jed MacKay, Netho Diaz, and Sean Parson, as Psylocke argues with Cyclops, most likely about attending the Hellfire Vigil. x-men: hellfire vigil #1 first look ...

Sanofi agreed to pay $8.00 per share in cash at closing, a significant premium over Vigil's closing price of $2.31 on Wednesday, for a total of $470 million. The company will pay an additional $2. ...

Vigil has reported positive data from a Phase I clinical trial (NCT06343636) evaluating VG-3927 in healthy volunteers. The drug demonstrated a favourable safety and tolerability profile across all ...

Sanofi SAN 0.23% said it entered an agreement to acquire Vigil Neuroscience VIGL 0.00% for approximately $470 million, a deal that adds a new investigational treatment for Alzheimer’s disease to ...